MARKET

ATTO

ATTO

Attovia Therapeutics Inc
NASDAQ
15.19
-0.08
-0.52%
After Hours: 15.19 0 0.00% 19:30 10/30 EDT
OPEN
15.30
PREV CLOSE
15.27
HIGH
15.99
LOW
13.77
VOLUME
146.67K
TURNOVER
--
52 WEEK HIGH
28.00
52 WEEK LOW
12.94
MARKET CAP
693.44M
P/E (TTM)
-16.6120
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ATTO last week (1019-1023)?
Weekly Report · 4d ago
Attovia Therapeutics Becomes Oversold (ATTO)
NASDAQ · 10/23 20:35
Weekly Report: what happened at ATTO last week (1012-1016)?
Weekly Report · 10/19 10:34
Attovia Therapeutics: Buy Rating Reaffirmed on Pipeline Momentum and Upcoming Catalysts, Price Target Unchanged at $30
TipRanks · 10/14 10:36
Weekly Report: what happened at ATTO last week (1005-1009)?
Weekly Report · 10/12 10:41
Weekly Report: what happened at ATTO last week (0928-1002)?
Weekly Report · 10/05 10:40
Attovia Therapeutics To Present New Clinical, Translational, And Preclinical Data Across Its Pipeline At EADV Congress And FCD 2026
Benzinga · 09/28 20:06
Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026
Barchart · 09/28 15:05
More
About ATTO
Attovia Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases with high unmet need. Its lead pipeline candidates target commercially validated pathways and are designed through its ATTOBODY biologics platform to deliver improved treatments relative to the standards of care. Its ATTOBODY platform uses an evolution-driven, high-throughput process which allows for discovery and creation of a high diversity of potential product candidates. It is developing a pipeline of novel biotherapeutics for the treatment of immune-mediated diseases. Its first two product candidates for its immune-dermatology franchise, ATTO-1310 and ATTO-2306, have the potential to treat patients suffering from pruritic and lesional diseases. Its third program, ATTO-1091, broadens its reach to other inflammatory diseases, such as IBD, a therapeutic area with substantial unmet need. ATTO-1310 is an ATTOBODY-based therapeutic targeting interleukin-31.

Webull offers Attovia Therapeutics stock information, including NASDAQ: ATTO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATTO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATTO stock methods without spending real money on the virtual paper trading platform.